Baxter CDMO BioPharma Solutions names Franco Negron as CEO ahead of proposed sale
25 Aug 2023
Executive ChangeAcquisition
Baxter’s CDMO arm, BioPharma Solutions, has announced a new CEO will take the reins following its proposed sale to private equity company Advent International and investment outfit Warburg Pincus for $4 billion.
Advent and Warbug picked Novartis veteran Franco Negron to lead the charge. Negron has more than 30 years of experience in the manufacturing and pharma industry, and previously served as CEO of the medical technology company ApiJect and held leadership positions at contract manufacturer Patheon before Thermo Fisher acquired it in 2017. He also served at Valeant Pharmaceuticals.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.